CJC-1295 vs Ipamorelin

Growth hormone secretagogues (GHS) like CJC‑1295 and ipamorelin are often discussed together for body composition, recovery, and “anti‑aging,” yet they differ in receptor targets, pharmacokinetics, and human evidence.131415161718 Understanding where data actually exist—and where it does not—helps separate mechanistic hope from documented effect.

• CJC‑1295: long‑acting GHRH analogue; prolonged elevations in GH and IGF‑1 after single injections in humans.1819
• Ipamorelin: selective GHS targeting the GHRP‑like receptor; shorter‑acting but highly GH‑selective with minimal ACTH/cortisol effects in preclinical models.1516

CJC‑1295

• Modified GHRH(1‑29) analogue; stimulates GHRH receptors on pituitary somatotrophs to enhance physiologic GH pulses.1718
• DAC‑associated formulations bind to serum albumin, significantly extending half‑life and allowing infrequent dosing.1918

Ipamorelin

• Pentapeptide (Aib‑His‑D‑2‑Nal‑D‑Phe‑Lys‑NH₂) classed as a GHS that activates the GHRP‑like receptor (ghrelin receptor family) to trigger GH release.1615
• Preclinical profiling showed potent GH release in rats and swine with markedly less effect on ACTH and cortisol compared with GHRP‑6, suggesting higher pituitary selectivity.1516

CJC‑1295

• In a phase 1 study, single subcutaneous injections in healthy adults produced 2‑ to 10‑fold increases in mean GH and 1.5‑ to 3‑fold increases in IGF‑1, persisting for up to 6–11 days depending on dose.18
• The estimated half‑life was around 5.8–8.1 days, confirming long‑acting behavior and supporting weekly or less frequent dosing.18

Ipamorelin

• Early human work (summarized by clinical overviews) reports significant GH rises in healthy elderly subjects after single doses, without parallel rises in cortisol, consistent with preclinical selectivity.1413
• A small randomized trial cited in secondary sources describes increased lean body mass and IGF‑1 in growth hormone‑deficient adults over 16 weeks of ipamorelin vs placebo, but this literature is relatively limited and not widely replicated.14

Overall, CJC‑1295’s human data focus more on pharmacokinetics and hormone profiles in healthy volunteers, while ipamorelin has smaller targeted deficiency‑oriented trials and a larger preclinical footprint.131617141518

• CJC‑1295 remains an investigational compound; it is not widely approved as a stand‑alone therapy, and large outcome‑based phase 3 trials are lacking.1718
• Ipamorelin is likewise not approved as a general GH therapy in most jurisdictions, with clinical guidance emphasizing that it lacks robust long‑term safety and efficacy data.13

In contrast, sermorelin (another GHRH analogue) has clearer regulatory pathways in some countries for GH deficiency, which is why it is more commonly used in legitimate HRT settings than these research secretagogues.2021

• Both agents increase GH and IGF‑1, raising theoretical concerns about long‑term neoplastic risk and fluid retention, analogous to other GH‑enhancing strategies, though long‑term data are sparse.14171318
• CJC‑1295, due to its long half‑life, may lead to prolonged hormonal exposure if adverse effects or supraphysiologic levels occur, limiting dose‑adjustment agility compared with shorter‑acting agents.1918
• Ipamorelin’s GH selectivity (minimal ACTH/cortisol response in preclinical models) may offer a cleaner endocrine profile than first‑generation GHRPs, but this does not substitute for long‑term safety trials.1615

1. Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone (GH) and insulin‑like growth factor‑1 (IGF‑1) by CJC‑1295, a long‑acting GHRH analog, in healthy adults. J Clin Endocrinol Metab. 2006.
2. Johns Hopkins / related citation. Once‑daily administration of CJC‑1295, a long‑acting growth hormone–releasing hormone analog, normalizes growth in GHRH‑knockout mice. (Preclinical study.)
3. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552–561.
4. DrOracle. What is the clinical usage of ipamorelin (growth hormone secretagogue)? Clinical overview of ipamorelin data and use‑cases.
5. Paragon Sports Medicine. Ipamorelin Peptide | Growth Hormone Support. Summary of mechanism, indications, and safety considerations.
6. Sermorelin.me. Ipamorelin: Pioneering the Era of Selective Growth Hormone Secretagogues. Mechanistic and preclinical summary.
7. Barpath Fitness. Peptide Therapy for Injuries, Performance, Health & More. Contextual comparison of secretagogues and approved GH therapies.